Balanced news tone
News Sentiment
CTNM sentiment intelligence
Contineum Therapeutics, Inc. Class A Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
51
Balanced news tone
56 relevant articles
News tone and price action are not far from neutral.
86/100 classification confidence.
directly relevant articles
high-authority source matches
+0.6% over one week, +27.9% over four weeks, trend active, and near fair-value range.
Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
86/100 classification
One-week reaction
0.6%
Price digesting
Trend fit
Trend active
27.9% over four weeks
Fair value
23.6%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
10
Neutral
38
Negative
8
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Investing.com
Direct company coverage
Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock
Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 1,040 shares of the company's Class A Common Stock for a total of $16,640 on July 8 and 9, 2026. These sales followed an exercise of stock options at a price of $1.01 per share and were conducted under a 10
- Tone
- Negative 41/100
- Event
- Market update
- Published
- 11 Jul 2026 14:41
- Source
- Investing.com
Stock Titan
Direct company coverage
Contineum Therapeutics (NASDAQ: CTNM) CSO sells 1,040 shares, exercises options
Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, exercised options for 1,040 shares at $1.01 each and subsequently sold those shares at $16.00 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in September 202
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 21:40
- Source
- Stock Titan
Investing.com India
Direct company coverage
Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock By Investing.com
Daniel S. Lorrain, CSO at Contineum Therapeutics (NASDAQ:CTNM), sold $16,640 worth of Class A Common Stock after exercising stock options. These transactions, executed under a 10b5-1 trading plan, occurred as CTNM stock approached its 52-week high, with a 283% return over the pas
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 21:40
- Source
- Investing.com India
Market source
Direct company coverage
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 16:00
- Source
- Market source
Investing.com Canada
Direct company coverage
Form 4 Contineum Therapeutics Inc For: 8 July By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 23:03
- Source
- Investing.com Canada
Stock Titan
Direct company coverage
Contineum (CTNM) CEO sells 2,500 shares under Rule 10b5-1 plan
Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 2,500 shares at $1.01 per share and subsequently sold those 2,500 shares at $16.00 per share on July 8, 2026. These transactions, valued at $40,000 for the sale, were conducted under a pre-arranged Rule 10
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 22:40
- Source
- Stock Titan
Investing.com
Direct company coverage
Contineum Therapeutics CEO Stengone sells $40,000 in shares
Carmine N. Stengone, CEO of Contineum Therapeutics, sold 2,500 shares of Class A Common Stock for $40,000, following the exercise of stock options. This transaction was executed under a pre-arranged 10b5-1 trading plan, occurring while the stock traded near its 52-week high and a
- Tone
- Negative 37/100
- Event
- Market update
- Published
- 08 Jul 2026 22:40
- Source
- Investing.com
Investing.com South Africa
Direct company coverage
Contineum Therapeutics CSO Daniel Lorrain sells $594,578 in stock By Investing.com
Contineum Therapeutics' Chief Scientific Officer, Daniel Lorrain, sold approximately $594,578 worth of company stock through multiple transactions on June 30 and July 1, 2026. These sales were conducted under a pre-arranged 10b5-1 trading plan and involved exercising stock option
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 03 Jul 2026 11:40
- Source
- Investing.com South Africa
Investing.com Canada
Direct company coverage
Form 4 Contineum Therapeutics Inc For: 2 July By Investing.com
This article reports on a Form 4 filing for Contineum Therapeutics Inc. on July 2nd. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The article indica
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 11:13
- Source
- Investing.com Canada
Stock Titan
Direct company coverage
Contineum (NASDAQ: CTNM) CSO sells 37,179 shares and exercises 33,009 options
Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, recently sold 37,179 shares of Class A Common Stock and exercised options for 33,009 shares. These transactions, conducted under a pre-arranged Rule 10b5-1 trading plan, took place on June 30 and July 1, 2026. A
- Tone
- Negative 29/100
- Event
- Market update
- Published
- 02 Jul 2026 22:10
- Source
- Stock Titan
Investing.com Nigeria
Direct company coverage
Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock By Investing.com
Contineum Therapeutics' Chief Medical Officer, Tim Watkins, sold 10,833 shares of company stock for $173,590 after exercising stock options under a pre-arranged trading plan. This transaction occurred amidst a significant surge in the stock's value, which has gained almost 300% i
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 00:18
- Source
- Investing.com Nigeria
Investing.com
Direct company coverage
Contineum Therapeutics CEO Stengone sells $160,080 in stock
Contineum Therapeutics CEO Carmine N. Stengone sold 10,000 shares of company stock for $160,080 and acquired 10,000 shares through option exercises for $10,725, both under a pre-arranged trading plan. These transactions occurred on June 30, 2026, with the sale happening near the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 00:08
- Source
- Investing.com
Investing.com Nigeria
Direct company coverage
Form 4 Contineum Therapeutics Inc For: 1 July By Investing.com
This article reports on a Form 4 filing for Contineum Therapeutics Inc (CTNM) for activity on July 1st. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The article provides the title and source, indicating it's a routine fina
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 23:10
- Source
- Investing.com Nigeria
Stock Titan
Direct company coverage
[Form 4] Contineum Therapeutics, Inc. Insider Trading Activity
Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 10,000 shares of Class A Common Stock and subsequently sold them in an open-market transaction at a weighted average price of $16.008 per share. These transactions were executed under a pre-arranged Rule 1
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 23:08
- Source
- Stock Titan
Stock Titan
Direct company coverage
Contineum (NASDAQ: CTNM) CMO sells 10,833 shares after option exercise
Contineum Therapeutics, Inc.'s CMO & Head of Development, Tim Watkins, exercised stock options for 10,833 shares at $4.50 per share and subsequently sold them at a weighted average price of $16.0242 per share on June 30, 2026. This transaction was conducted under a Rule 10b5-1 tr
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 23:08
- Source
- Stock Titan
Investing.com
Direct company coverage
Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock
Contineum Therapeutics' Chief Medical Officer, Tim Watkins, sold 10,833 shares of company stock for $173,590 after acquiring them through stock option exercises. These transactions were executed under a pre-arranged trading plan, coinciding with a significant surge in the stock's
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 01 Jul 2026 19:16
- Source
- Investing.com
Stock Titan
Direct company coverage
[144] Contineum Therapeutics, Inc. SEC Filing
This SEC Form 144 filing by Contineum Therapeutics, Inc. details a proposed sale of 10,000 shares of common stock with an aggregate market value of $150,000. The shares were acquired on June 30, 2026, through the exercise of stock options and are intended to be sold through Morga
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 12:42
- Source
- Stock Titan
Stock Titan
Direct company coverage
Insider sales and option exercise at CTNM (NASDAQ: CTNM)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 07:00
- Source
- Stock Titan
BioSpace
Direct company coverage
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Contineum Therapeutics announced the publication of a manuscript in the Journal of Medicinal Chemistry detailing the discovery and characterization of PIPE-791, a potent and brain-penetrant LPAR1 antagonist. This compound is currently in a global Phase 2 clinical trial for idiopa
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 01 Jul 2026 03:39
- Source
- BioSpace
Stock Titan
Direct company coverage
Contineum Therapeutics (CTNM) grants director 19,000 stock options at $14.19
Contineum Therapeutics director Evert B. Schimmelpennink was granted stock options for 19,000 shares of Class A Common Stock at an exercise price of $14.19 per share under the company's 2024 Equity Incentive Plan. This is a compensation-related award, not an open-market purchase.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 03:07
- Source
- Stock Titan
Investing.com Australia
Direct company coverage
Contineum Therapeutics CEO Stengone sells $160,080 in stock By Investing.com
Carmine N. Stengone, CEO of Contineum Therapeutics (NASDAQ:CTNM), recently sold 10,000 shares of company stock for $160,080, with the transaction occurring through a pre-arranged 10b5-1 trading plan. On the same day, he acquired 10,000 shares by exercising stock options at a lowe
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 02:10
- Source
- Investing.com Australia
Stock Titan
Direct company coverage
Contineum’s PIPE-791 paper says Phase 2 drug may target fibrosis
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 30 Jun 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
CTNM (NASDAQ) notice to sell 28,826 shares; broker Morgan Stanley named
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
Contineum (CTNM) awards non-employee director 19,000 stock options
Contineum Therapeutics (CTNM) has granted 19,000 stock options to non-employee director Diego Miralles as part of its standard board compensation program. The options, with an exercise price of $14.19 per share, were awarded under the company's 2024 Equity Incentive Plan and vest
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 22:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Contineum Therapeutics (CTNM) awards director 19,000-share stock option grant
Contineum Therapeutics (CTNM) director Olivia C. Ware received a grant of stock options for 19,000 shares of Class A common stock, with an exercise price of $14.19 per share. These options were issued under the 2024 Equity Incentive Plan as part of the non-employee director compe
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 21:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Contineum Therapeutics (CTNM) director receives 19,000 stock options grant
Contineum Therapeutics director Lori Lyons-Williams was granted 19,000 stock options under the company’s 2024 Equity Incentive Plan. These options, tied to Class A Common Stock, have an exercise price of $14.19 per share and expire on June 25, 2036. The grant is part of the Non-E
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 21:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Contineum Therapeutics (CTNM) elects Class II directors, ratifies Ernst & Young as 2026 auditor
Contineum Therapeutics, Inc. (CTNM) held its 2026 Annual Meeting of Stockholders on June 26, 2026. During the meeting, stockholders elected three Class II directors—Evert Schimmelpennink, Lori M. Lyons-Williams, and Diego Miralles, M.D.—to serve until the 2029 annual meeting. Add
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 20:39
- Source
- Stock Titan
The Globe and Mail
Direct company coverage
Contineum Stockholders Hold 2026 Virtual Annual Meeting
Contineum Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 26, 2026. Stockholders re-elected three Class II directors and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. Anal
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 13:39
- Source
- The Globe and Mail
TradingView
Direct company coverage
Contineum Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:CTNM)
This article provides an overview of Contineum Therapeutics, Inc. (NASDAQ: CTNM) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details financial estimates like earnings per share and revenue, and notes that the c
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 26 Jun 2026 08:10
- Source
- TradingView